Cholinergic agonist-antagonist interactions on neocortical and limbic EEG activation.
D000109:Acetylcholine / Q000494:pharmacology; D000679:Amygdala / Q000187:drug effects; D000818:Animals; D001143:Arousal / Q000187:drug effects*; D001285:Atropine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D002415:Cats; D002540:Cerebral Cortex / Q000187:drug effects; D004569:Electroencephalography; D006624:Hippocampus / Q000187:drug effects; D008464:Mecamylamine / Q000494:pharmacology; D009538:Nicotine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology*; D010277:Parasympathomimetics / Q000494:pharmacology*; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D000644:Quaternary Ammonium Compounds / Q000494:pharmacology; D012890:Sleep / Q000187:drug effects*
D010276:Parasympatholytics; D010277:Parasympathomimetics; D000644:Quaternary Ammonium Compounds; D010862:Pilocarpine; D008464:Mecamylamine; D009538:Nicotine; D001285:Atropine; D010830:Physostigmine; D000109:Acetylcholine